Navigation Links
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients taking once-daily Lialda remained relapse free at the end of 12 months

WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroenterology (BSG) meeting in Glasgow, Scotland in March 2007 showed Shire plc's Lialda(mesalamine) is well tolerated in mild to moderate UC patients. Today, secondary endpoints of study 303 were presented as post-hoc analyses at Digestive Disease Week (DDW).

Approved by the FDA on January 16, 2007, for the induction of remission in patients with active, mild to moderate UC, LIALDA is the first and only oral once-daily mesalamine on the market. Safety and effectiveness have been established for up to eight weeks. LIALDA is being evaluated for longer term use.

Long-term remission and relapse rates on LIALDA (abstract # T1296)

A post-hoc analysis of study 303 evaluated maintenance of remission and relapse rates over 12 months. Remission was defined using stringent clinical and endoscopic criteria: modified UC Disease Activity Index (UC-DAI) score of less than or equal to 1, with scores of 0 for rectal bleeding and stool frequency, a combined Physician's Global Assessment and sigmoidoscopy score of less than or equal to 1, with a sigmoidoscopy score reduction of greater than or equal to 1 point from baseline and no mucosal friability. Relapse was defined as withdrawing from the study due to a need for alternative therapy for UC.

Overall, a total of 459 patients entered the maintenance phase of study 303. Of these patients, 362 patients met the stringent remission criteria (clinical and endoscopic as defined above) at baseline (in parent studies 301 and 302 -- LIALDA's eight-week, phase III, placebo-controlled trials that demonstrated efficacy for the induction of remission in active, mild to moderate
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
(Date:10/25/2014)... SANTA MONICA, Calif. , Oct. 24, 2014 ... medtech leaders over friendly robotic competition at the  ... Conference on October 29-30 th at ... The event will highlight local student built robots ... and Technology" (FIRST) competition.  FIRST students and mentors ...
(Date:10/25/2014)... Oct. 24, 2014   Metanome, Inc. , a ... services and data analysis, was the genomic sequencing provider ... Phase I/II clinical trial of SER 109, an Ecobiotic® ... Clostridium difficile infections (CDI). Metanome has ... R&D and clinical programs. Such genomic characterization has enabled ...
(Date:10/25/2014)... HILL, N.C. , Oct. 24, 2014 /PRNewswire/ ... teams can provide a company access to diverse ... emerging markets, and round-the clock business hours for ... overcoming difficult hurdles. According to ... team disappointments, such as seeing a project not ...
Breaking Medicine Technology:Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 2Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 3Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2
... Amicus Therapeutics (Nasdaq: FOLD ) today announced ... No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods of ... isofagomine, the active ingredient in the Company,s investigational drug Plicera(TM) ... disease. The patent will expire in 2027. John ...
... CONFIRM SAFETY AND EFFICACY FOR ROOM TEMPERATURE STORAGENANTONG ... Bulletin Board: SNBP) is pleased to announce that ... skeletal muscle relaxant marketed as Kutai in China, ... multi-center Phase IV Clinical Study investigated the safety ...
Cached Medicine Technology:Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 2Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 3Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing 2Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing 3
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for online ... Bob Seger & The Silver Bullet Band tickets for ... going on sale October 25 and are expected to ... the selection of tickets for Bob Seger & The ... is touring North America beginning next month, and he ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
(Date:10/22/2014)... October 22, 2014 On October 22, ... featuring skin diseases both fictional and real. The ... a nonprofit organization committed to advocacy and philanthropy in ... will take the opportunity to impart truth and clarity ... , There are many misconceptions about Morgellons Disease ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... clinical trials on a new investigational drug being developed ... been successfully completed. Completion of the initial phase ... prepared by researchers at Cardiff University,s Welsh School of ... an approved medicine have significantly improved. Approximately ...
... N.C. Millions of patients with advanced disease in palliative ... easily. But a new study from Duke University Medical ... intervention, and among those who do benefit, it doesn,t make ... just plain old room air both offer equal benefit. ...
... Reporter , THURSDAY, Sept. 2 (HealthDay News) -- An ... two hours, making only one doctor visit necessary before ... advance against a disease that kills nearly 2 million ... "This is a very important discovery," said infectious disease ...
... and a little serendipity led a Northwestern University research team ... used for gas storage and food and medical technologies. And ... first known all-natural metal-organic frameworks (MOFs) that are simple to ... the Northwestern MOFs you can pop into your mouth and ...
... Stem cells might be thought of as trunks in the ... can turn into a dazzling variety other cellskidney, brain, heart ... the capacity to turn into virtually any cell type in ... of cell therapies, the conquering of age-old diseases or even ...
... September, 2010 - Elsevier announced today the publication of ... Andropause Society (EMAS) in the journal Maturitas ... post-reproductive health of women. The statements cover the ... epilepsy, endometriosis and premature ovarian failure. Each statement ...
Cached Medicine News:Health News:First clinical trials successfully completed on potent new hepatitis C drug 2Health News:Study challenges value of oxygen therapy in end-of-life care 2Health News:Study challenges value of oxygen therapy in end-of-life care 3Health News:Experimental TB Test Called Fast and Accurate 2Health News:Experimental TB Test Called Fast and Accurate 3Health News:Edible nanostructures 2Health News:Edible nanostructures 3Health News:Study finds that cancer-causing gene crucial in stem cell development 2Health News:Study finds that cancer-causing gene crucial in stem cell development 3Health News:EMAS publishes position statements about the post-reproductive health of women 2
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
Medicine Products: